Breast Cancer Coverage From Every Angle

Recent News

ASCO 2018: Weighing Benefits/Risks of Exemestane Therapy in Premenopausal Women With Breast Cancer
FDA Grants Priority Review to Talazoparib for Metastatic Breast Cancer With BRCA Mutation
2018 ASCO: Ribociclib Plus Fulvestrant for Postmenopausal Patients With Advanced Breast Cancer
ASCO 2018: Can Lymph Node Irradiation Improve Outcomes in Breast Cancer?
ASCO 2018: SANDPIPER Trial Studies Novel Combination Therapy for Advanced Breast Cancer
ASCO 2018: TAILORx Shows Most Women With Early-Stage Breast Cancer Can Avoid Chemotherapy
FDA Accepts New Drug Application for Larotrectinib in Treatment of Certain Solid Tumors
ACR and SBI Offer New Guidance for Breast Cancer Screening
Study Finds Link Between Histone Levels and Efficacy of Radiation Therapy
ASCO 2018 Preview: Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer
ASBrS 2018: Are Current Genetic Testing Guidelines for Breast Cancer Too Restrictive?
ASBrS 2018: Preventing Lymphedema Related to Breast Cancer
ASBrS 2018: Impact of Screening Mammography on Patient Outcomes in Breast Cancer
ASTRO Issues New Clinical Guideline for Whole-Breast Radiation Therapy
AACR 2018: How Splicing Factors May Impact Breast Cancer Cell Mitosis
ESTRO 37: Quality of Life With Targeted Radiotherapy for Early Breast Cancer
FDA Grants Fast Track Designation to Balixafortide Plus Eribulin for Metastatic Breast Cancer
AACR 2018: Results of the Pan-Gynecologic Molecular Study
Long-Term Patterns of Chemotherapy-Induced Neuropathy in Women With Breast Cancer
Using Metabolomics to Understand Body Mass Index–Breast Cancer Link
EBCC-11: Omission of Sentinel Lymph Node Biopsy in Subset of Patients With Breast Cancer
EBCC-11: Survival Rates After Prophylactic Mastectomy in BRCA-Mutation Carriers
EBCC-11: Predicting Contralateral Breast Cancer Risk in Women With BRCA Mutation
Effect of Dietary Xenoestrogens on Cellular Metabolism in Breast Cancer
Screening Strategies for Women With Increased Breast Density
AACR 2018 Preview: Acquired HER2 Mutations and Resistance to Hormone Therapy for Breast Cancer
ACC 2018: Managing Cardiotoxicity in Patients Receiving Breast Cancer Chemotherapy
FDA Authorizes First Direct-to-Consumer Test That Reports Mutations in Breast Cancer Genes
Risk of Cardiovascular Diseases in Patients With Breast Cancer
Cancer Survivorship Symposium: Exercise and Arm Mobility After Breast Cancer Surgery
FDA Expands Approval of Abemaciclib to Initial Treatment of Advanced Breast Cancer
Survival Rates and BRCA Status in Younger Women With Breast Cancer
Predictors of Prognosis Discovered in Triple-Negative Breast Cancer
Researchers Evaluate the Need for Breast Biopsies After Treatment for Early Breast Cancer
Two Genes May Link Lynch Syndrome and Breast Cancer
Smoking and Risk of Breast Cancer
Tumor-Infiltrating Lymphocytes and Breast Cancer Prognosis
Novel Treatment Studied in Triple-Negative Breast Cancer
Chemotherapy-Free Combination Regimen in HER2-Positive Breast Cancer
AACR Obesity and Cancer Conference: Breast Cancer Risk in Postmenopausal Women With Normal BMI
Physical Activity May Lead to Better Sleep Quality in Breast Cancer Survivors
Soy and Cruciferous Vegetable Intake in Female Breast Cancer
Neoadjuvant Combination Therapy in Early-Stage Triple-Negative Breast Cancer
Role of Olaparib in HER2-Negative Metastatic Breast Cancer Under Study
Neoadjuvant Trial of Dual HER2 Targeting Plus Lapatinib
Overall Survival Results From Early Breast Cancer TEXT and SOFT Trials
FDA Grants Expanded Approval to Olaparib for BRCA-Mutant Metastatic Breast Cancer
Long-Term Weekly Paclitaxel vs. Nab-paclitaxel or Ixabepilone as First-Line Therapy for Metastatic Breast Cancer
Phase III Trial Investigates Atezolizumab in Triple-Negative Breast Cancer
Substituting Nab-paclitaxel for Paclitaxel in Invasive Breast Cancer
Primary Endocrine Therapy for Estrogen Receptor–Positive Ductal Carcinoma in Situ
FDA Grants Breakthrough Therapy Designation to Ribociclib in Combination Therapy for Advanced Breast Cancer
Potential Role of Abemaciclib in Prognostic Breast Cancer Subgroups
FDA Grants Clearance to Noninvasive Stereotactic Radiotherapy System for Breast Cancer
FDA Approves Pertuzumab Combination Therapy for HER2-Positive Breast Cancer
SABCS 2017: Enzalutamide and Exemestane in Hormone Receptor–Positive Breast Cancer
SABCS 2017: Treatment With GnRHa and Ovarian Function in Women Receiving Chemotherapy for Breast Cancer
SABCS 2017: Duration of Zoledronate Treatment After Adjuvant Chemotherapy
SABCS 2017: Sacituzumab Govitecan as Late Therapeutic Option in Metastatic Breast Cancer
SABCS 2017: Increasing the Dose Intensity of Chemotherapy for Breast Cancer
SABCS 2017: Can Perioperative Aromatase Inhibitor Treatment Predict Long-Term Outcomes in Early Breast Cancer?
SABCS 2017: Shorter vs. Longer Duration Postadjuvant Anastrozole in HER2-Positive Breast Cancer
SABCS 2017: Extended Trastuzumab Treatment in Early-Stage HER2-Positive Breast Cancer
SABCS 2017: First-Line Ribociclib and Endocrine Therapy in Advanced Breast Cancer
SABCS 2017: Tamoxifen Plus Ovarian Function Suppression Regimen for Early Breast Cancer
Combining Focused Ultrasound and Immunotherapy to Treat Breast Cancer
Effect of Pomegranate Extract on Breast Cancer Stem Cells
FDA Approves Biosimilar to Trastuzumab for HER2-Positive Breast Cancer
Outcomes With Regional Anesthesia in Breast Cancer Surgery
Intermittent Versus Continuous Chemotherapy Scheduling in Metastatic Breast Cancer
Benefits Reported for Breast Cancer Patients Who Regularly Practice Yoga
Influence of Race, Insurance Status, and Accessibility on Immediate Breast Reconstruction Rates
Combination of Alisertib and TAK-228 in Triple-Negative Breast Cancer
New Indication for Fulvestrant in Combination Therapy for Advanced Breast Cancer
AORTIC 2017: Are Skin Lighteners and Hair Relaxers Associated With Increased Risk of Breast Cancer?
First-Line Ribociclib and Letrozole in Advanced Breast Cancer
Are Standard-of-Care Treatments in Clinical Trials Really ‘Standard’?
AACR-NCI-EORTC 2017: Potential of Antibiotic Salinomycin in Breast Cancer
CoBrCa 2017: Ovarian Function Suppression Plus AI in Young Women at Risk of Breast Cancer Recurrence
AACR-NCI-EORTC 2017: Potential Novel Agent for Estrogen Receptor–Positive Breast Cancer
CoBrCa 2017: Genetic Testing for Women With Breast Cancer
ACS 2017: Can Socioeconomic Status Predict Quality of Life in Breast Cancer Survivors?
ACS 2017: Women at Higher Risk of Breast Cancer and MRI Screening
Intravenous Rolapitant Approved by FDA for Delayed Chemotherapy-Induced Nausea and Vomiting
FDA Grants Priority Review for Olaparib in Metastatic Breast Cancer
Novel Strategies for Preventing Chemotherapy-Induced Peripheral Neuropathy
Fertility Preservation in BRCA-Positive Women With Breast Cancer
Priority Review Granted by FDA for Abemaciclib as First-Line Treatment for Advanced Breast Cancer
Further Efficacy Outcomes From OlympiAD Trial of Olaparib in Advanced Breast Cancer
ASTRO 2017: Biologic Markers of Primary Breast Cancer and Brain Metastases
ASTRO 2017: Neoadjuvant Radiation Therapy Before Surgery in Locally Advanced Breast Cancer
Priority Review Granted for Adjuvant Combination Treatment for HER2-Positive Breast Cancer
TIL Levels and Response to Pembrolizumab in Metastatic Triple-Negative Breast Cancer
ASTRO 2017: Stereotactic Radiosurgery for Brain Metastases From Breast Cancer
FDA Approves Abemaciclib for Treatment of Breast Cancers That Progress With Endocrine Therapy
ASTRO 2017: Accelerated Breast Radiation Therapy After Mastectomy
ASTRO 2017: Shorter Course of Radiation Therapy for Younger Women With Breast Cancer
Tumor Microenvironment in Racially Distinct Triple-Negative Breast Cancers
ESMO 2017: Neoadjuvant Letrozole Plus Palbociclib in Luminal Breast Cancer
ESMO 2017: Comparison of Biosimilar ABP 980 and Trastuzumab in HER2-Positive Breast Cancer
ESMO 2017: Extended Adjuvant Neratinib for Early-Stage HER2-Positive Breast Cancer
ESMO 2017: Comparison of Two Adjuvant Therapies for Early Breast Cancer
ESMO 2017: Neoadjuvant Combination Therapy With Taselisib and Letrozole in Early Breast Cancer
ESMO 2017: Adding Abemaciclib to Endocrine Therapy for Advanced Breast Cancer
ESMO 2017: Nivolumab After Induction Therapy in Triple-Negative Breast Cancer
ESMO 2017: Adding Everolimus to Letrozole in Metastatic Breast Cancer Therapy
ESMO 2017: Chemotherapy for Small Node-Negative Breast Tumors
Impact of Surgical Modality on Breast-Specific Sensuality
Triple-Negative Breast Cancer: Genomic Metrics and Immune Infiltration
Mammography Device With Option for Patient-Assisted Compression Cleared by FDA
DS-8201 Granted Breakthrough Therapy Designation for HER2-Positive Metastatic Breast Cancer
FDA Approves Expanded Use of Fulvestrant as Monotherapy in Breast Cancer
Neoadjuvant Radiotherapy for Early-Stage Breast Cancer
ASCO Breast Cancer Guideline Update on Use of 70-Gene Test
Nipple-Sparing Mastectomy and Breast Cancer Recurrence
Risk-Reducing Mastectomy vs. Surveillance for Women With BRCA Mutation and History of Ovarian Cancer
Ado-trastuzumab Emtansine as First-Line Therapy for Metastatic Breast Cancer in MARIANNE Trial
Patient-Reported Outcomes in Relation to Fat Grafting in Postmastectomy Breast Reconstruction
Recent Trends in Male Breast Cancer
Leading Cause of Death in Patients With Breast Cancer
Neratinib Approved by FDA for Extended Adjuvant Treatment of HER2-Positive Breast Cancer
ASCO 2017: Ado-trastuzumab Emtansine in Resistant HER2-Positive Breast Cancer
Priority Review Granted for Abemaciclib in Advanced Breast Cancer
ASCO 2017: First-Line Addition of Bevacizumab to Endocrine Therapy in Advanced Breast Cancer
ASCO 2017: Dual HER2 Blockade in Metastatic Breast Cancer
ASCO 2017: Duration of Adjuvant Trastuzumab for HER2-Positive Breast Cancer
Implementing BRCA1/2 Genetic Testing in Patients With Breast Cancer
ASCO 2017: MONALEESA-2 Update on Combination of Ribociclib and Letrozole
Joint Position Statement on Bone Loss Associated With Aromatase Inhibitors
ASCO 2017: Talazoparib in Metastatic Breast Cancer With a Germline BRCA1/2 Mutation
ASCO 2017: Abemaciclib Plus Fulvestrant in Endocrine-Resistant Breast Cancer
ASCO 2017: Adding a Second HER2 Blocker to Standard of Care in Invasive Breast Cancer
ASCO 2017: Addition of Pembrolizumab to Standard Therapy in High-Risk Breast Cancer
ASCO 2017: Olaparib Monotherapy in Metastatic Breast Cancer
ASCO 2017: Safety of Pregnancy After Breast Cancer
ACOG 2017: Prolonged Tamoxifen vs Oophorectomy in Estrogen Receptor–Positive Breast Cancer
ACOG 2017: Debate Continues Over Timing and Frequency of Breast Cancer Screening
Updated Clinical Practice Guidelines on Integrative Therapies
ASBrS 2017: Is Adjuvant Whole-Breast Radiation Therapy Necessary for Ductal Carcinoma in Situ?
ASBrS 2017: Surgical Resection of Primary Tumors in Stage IV Breast Cancer
FDA Approves Co-Pack of Ribociclib and Letrozole for Metastatic Breast Cancer
IMPAKT 2017: Tumor-Infiltrating Lymphocyte Levels in HER2-Positive Breast Cancer
ASBrS 2017: Practice Patterns in Use of SLND After Neoadjuvant Chemotherapy
IMPAKT 2017: LAR Subtype of Triple-Negative Breast Cancer and CDK4/6 Inhibition
ASBrS 2017: Lumpectomy and Excisional Biopsy in an Outpatient Setting
ASBrS 2017: Risk of Lymphedema Related to Breast Cancer
ASBrS 2017: Contralateral Prophylactic Mastectomy for Ductal Carcinoma in Situ
Use of Dexamethasone Oral Solution in Patients Receiving Treatment for Breast Cancer
Predicting Local Metastases After Neoadjuvant Chemotherapy for Breast Cancer
AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
AACR 2017: Atezolizumab Associated With Survival Benefit in Triple Negative Breast Cancer
Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer
Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial
Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Cancer Patients
Buparlisib Phase III Findings: Glass Half Empty or Half Full?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.